Di erences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT2A and 5-HT2C receptors
Artículo
Open/ Download
Publication date
2002-04-04Metadata
Show full item record
Cómo citar
Acuña Castillo, Claudio
Cómo citar
Di erences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT2A and 5-HT2C receptors
Author
Abstract
1 The pharmacological pro®le of a series of (+)-2,5-dimethoxy-4-(X)-phenylisopropylamines
(X=I, Br, NO2, CH3, or H) and corresponding phenylethylamines, was determined in Xenopus laevis
oocytes injected with cRNA coding for rat 5-HT2A or 5-HT2C receptors. The e cacy and relative
potency of these drugs were determined and compared to classical 5-HT2 receptor agonists and
antagonists.
2 The rank order of agonist potency at the 5-HT2A receptor was: a-methyl-5-HT=5-HT4m-
CPP4MK-212; at the 5-HT2C receptor the order was: 5-HT4a-methyl-5-HT4MK-2124m-CPP.
All these compounds were full agonists at the 5-HT2C receptor, but a-methyl-5-HT and m-CPP
showed lower e cacy at the 5-HT2A receptor.
3 4-(4-Fluorobenzoyl)-1-(4-phenylbutyl)piperidine (4F 4PP) was 200 times more potent as a 5-
HT2A antagonist than at 5-HT2C receptors. Conversely, RS 102221 was 100 times more potent as a
5-HT2C antagonist, con®rming their relative receptor selectivities.
4 The phenylisopropylamines were partial agonists at the 5-HT2A receptor, with Imax relative to 5-
HT in the 22+7 to 58+15% range; the corresponding phenylethylamines had lower or undetectable
e cacies. All these drugs had higher e cacies at 5-HT2C receptors; DOI was a full 5-HT2C agonist.
2C-I and the other phenylethylamines examined showed relative e cacies at the 5-HT2C receptor
ranging from 44+10% to 76+16%.
5 2C-N was a 5-HT2 receptor antagonist; the mechanism was competitive at the 5-HT2A, but non-
competitive at the 5-HT2C receptor. The antagonism was time-dependent at the 5-HT2C receptor but
independent of pre-incubation time at the 5-HT2A receptor subtype.
6 The a-methyl group determines the e cacy of these phenylalkylamines at the 5-HT2A and 5-
HT2C receptors.
Patrocinador
This research was partially funded by the Centre of Cell
Regulation and Pathology (FONDAP 13980001), the Millennium
Institutes for Fundamental and Applied Biology (MIFAB) and
Advanced Studies in Cell Biology and Biotechnology (CBB), and
DICYT grant 020091SB. The authors thank Dr P. Bull for
assistance in the replication of the 5-HT receptor clones and Prof
G. Owen for editorial assistance.
Quote Item
British Journal of Pharmacology, 136, 510- 519, 2002.
Collections